帕博利珠单抗联合多西他赛对比多西他赛治疗既往经治的转移性去势抵抗性前列腺癌:随机双盲III期KEYNOTE-921试验
KEYNOTE-921研究将515例既往经雄激素剥夺治疗和一种雄激素受体通路抑制剂后进展的转移性去势抵抗性前列腺癌患者随机分配至帕博利珠单抗联合多西他赛组或安慰剂联合多西他赛组。首次中期分析显示两组影像学无进展生存期无显著差异(HR 0.85,P=0.03),最终分析总生存期亦无显著差异(HR 0.92,P=0.17)。结论认为在多西他赛基础上加用帕博利珠单抗未显著改善疗效,当前标准治疗不变。
要点
- 帕博利珠单抗联合多西他赛对比安慰剂联合多西他赛,影像学无进展生存期无显著差异。
- 最终分析总生存期两组无显著差异,HR 0.92(95%CI 0.78-1.09)。
- 帕博利珠单抗组≥3级治疗相关不良事件发生率为43.2%,高于安慰剂组的36.6%。
核心结论
- 在多西他赛基础上加用帕博利珠单抗未显著改善既往经治转移性去势抵抗性前列腺癌患者的疗效结局,当前标准治疗保持不变。
研究设计与样本
- 随机双盲III期KEYNOTE-921试验(NCT03834506),纳入既往经雄激素剥夺治疗和一种雄激素受体通路抑制剂后进展的转移性去势抵抗性前列腺癌成人患者,按1:1随机分配至帕博利珠单抗联合多西他赛组(515例)或安慰剂联合多西他赛组(515例),两组均联用泼尼松。
- 双主要终点为盲法独立中心审查按前列腺癌工作组3修订的RECIST 1.1评估的影像学无进展生存期和总生存期,安全性为次要终点。
主要发现
- 首次中期分析(数据截止日期2021年9月27日)显示,帕博利珠单抗联合多西他赛组中位影像学无进展生存期为8.6个月(95%CI 8.3-10.2),安慰剂联合多西他赛组为8.3个月(95%CI 8.2-8.5),HR 0.85(95%CI 0.71-1.01),P=0.03。
- 最终分析显示,帕博利珠单抗联合多西他赛组中位总生存期为19.6个月(95%CI 18.2-20.9),安慰剂联合多西他赛组为19.0个月(95%CI 17.9-20.9),HR 0.92(95%CI 0.78-1.09),P=0.17。
- 帕博利珠单抗联合多西他赛组≥3级治疗相关不良事件发生率为43.2%,安慰剂联合多西他赛组为36.6%;两组分别有2例和7例参与者死于治疗相关不良事件。
- 肺炎是最常见的免疫介导不良事件,帕博利珠单抗联合多西他赛组发生率为7.0%,安慰剂联合多西他赛组为3.1%。
临床怎么用
- 原文结论指出,在多西他赛基础上加用帕博利珠单抗未显著改善疗效结局,当前标准治疗保持不变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov identifier: NCT03834506) evaluated the efficacy and safety of pembrolizumab or placebo plus docetaxel for previously treated mCRPC. METHODS: Adults with mCRPC who progressed after androgen-deprivation therapy and one ARPI were randomly assigned 1:1 to pembrolizumab or placebo plus docetaxel with concomitant prednisone. Dual primary end points were radiographic progression-free survival (rPFS) by blinded independent central review per Prostate Cancer Working Group 3-modified RECIST 1.1 and overall survival (OS). Safety was a secondary end point. RESULTS: Between May 30, 2019, and June 17, 2021, 515 participants were randomly assigned to pembrolizumab plus docetaxel and 515 to placebo plus docetaxel. Median time from random assignment to data cutoff date (June 20, 2022) at final analysis (FA) was 22.7 months (range, 12.1-36.7). At first interim analysis (data cutoff date: September 27, 2021), median rPFS was 8.6 months (95% CI, 8.3 to 10.2) with pembrolizumab plus docetaxel versus 8.3 months (95% CI, 8.2 to 8.5) with placebo plus docetaxel (hazard ratio [HR], 0.85 [95% CI, 0.71 to 1.01]; P = .03). At FA, median OS was 19.6 months (95% CI, 18.2 to 20.9) versus 19.0 months (95% CI, 17.9 to 20.9), respectively (HR, 0.92 [95% CI, 0.78 to 1.09]; P = .17). Grade ≥3 treatment-related adverse events occurred in 43.2% of participants who received pembrolizumab plus docetaxel and 36.6% of participants who received placebo plus docetaxel. Two and seven participants, respectively, died due to a treatment-related adverse event. Pneumonitis was the most common immune-mediated adverse event (7.0% v 3.1%). CONCLUSION: The addition of pembrolizumab to docetaxel did not significantly improve efficacy outcomes for participants with previously treated mCRPC. The current standard of care remains unchanged.
引用
- Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. J Clin Oncol. 2025. PMID: 40043230. doi:10.1200/JCO-24-01283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。